Dataset Information
Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma.
Ontology highlight
ABSTRACT: Background
Hepatoma arterial-embolization prognostic (HAP) score and its modifications (modified HAP [mHAP] and mHAP-II), consisting of some or all of the following factors of tumor size, number, alpha-fetoprotein, bilirubin, and serum albumin, have been found to predict outcomes after trans-arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). We investigated the feasibility of using HAP-related risk scores for dynamic risk assessment during repeated TACE.Methods
A total of 619 HCC patients treated with TACE from two institutions between 2003 and 2010 were included.Results
Patients with A-B class risk scores showed significantly better survival than those with C-D class risk scores at the first (median 43.7 vs. 21.5?months for mHAP-II, 35.2 vs. 10.2?months for mHAP, and 39.8 vs. 18.6?months for HAP; all P?ConclusionsAll HAP-related risk scores dynamically predicted outcomes during repeated TACE. Sequential risk assessment using mHAP-II best identified optimal candidates for repeated TACE.
SUBMITTER: Park Y
PROVIDER: S-EPMC6469056 | biostudies-literature | 2019 Apr
REPOSITORIES: biostudies-literature
Publications
Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma.
BMC cancer 20190416 1
<h4>Background</h4>Hepatoma arterial-embolization prognostic (HAP) score and its modifications (modified HAP [mHAP] and mHAP-II), consisting of some or all of the following factors of tumor size, number, alpha-fetoprotein, bilirubin, and serum albumin, have been found to predict outcomes after trans-arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). We investigated the feasibility of using HAP-related risk scores for dynamic risk assessment during repeated TACE.<h4>Methods</h4 ...[more]